Table 1 Patients information

Sexuality

0.569 (0.32)

 Male

15 (60%)

13 (52%)

 Female

10 (40%)

12 (48%)

Age

0.396 (0.72)

 ≤ 56

14 (56%)

11 (44%)

 > 56

11 (44)

14 (56%)

Tumor type

0.994 (0.34)

 SCC

5 (20%)

5 (20%)

 Lymphoma

3 (12%)

3 (12%)

 Adenocarcinoma

9 (36%)

7 (28%)

 Liemiosarcoma

1 (4%)

2 (8%)

 Hepatocellular carcinoma

1 (4%)

1 (4%)

 Angiosarcoma

1 (4%)

–

 breast Ductal carcinoma

2 (8%)

3 (12%)

 breast Lobular carcinoma

1 (4%)

1 (4%)

 Ovarian carcinoma

2 (8%)

3 (12%)

Tumor location

0.951 (0.05)

 Rectum

7 (28%)

6 (24%)

 Ovary

2 (8%)

3 (12%)

 Gastric

3 (12%)

3 (12%)

 Breast

3 (12%)

4 (16%)

 Liver

2 (8%)

1 (4%)

 Colon

1 (4%)

2 (8%)

 Larynx

2 (8%)

3 (12%)

 Hypo-pharynx

2 (8%)

2 (8%)

 Palate

2 (8%)

1 (4%)

 Lymphoma in neck

1 (4%)

–

Chemotherapy drug and dosage

0.999 (0.23)

 Cisplatin 30

2 (11.1%)

1 (5.3%)

 Cisplatin 50

8 (44.4%)

9 (47.3%)

 5FU 640

5 (27.7%)

6 (31.6%)

 5FU 700

1 (5.6%)

2 (10.5%)

 5FU 750

2 (11.1%)

1 (5.3%)

Radiotherapy dosage

0.095

 6000 cGy

5 (71.5%)

1 (16.7%)

 6600 cGy

0

1 (16.7%)

 7000 cGy

2 (28.5%)

4 (66.6%)